Greenwich LifeSciences, Inc. (NASDAQ:GLSI – Get Free Report) was the recipient of a significant growth in short interest in September. As of September 15th, there was short interest totalling 505,200 shares, a growth of 8.3% from the August 31st total of 466,600 shares. Based on an average daily volume of 46,500 shares, the days-to-cover ratio is currently 10.9 days. Currently, 8.5% of the shares of the stock are sold short.
Greenwich LifeSciences Price Performance
Shares of GLSI stock traded down $0.51 on Tuesday, hitting $13.86. The stock had a trading volume of 31,336 shares, compared to its average volume of 42,669. The company’s 50 day moving average price is $14.44 and its 200-day moving average price is $15.05. Greenwich LifeSciences has a 1 year low of $7.58 and a 1 year high of $21.44. The firm has a market capitalization of $178.52 million, a P/E ratio of -19.69 and a beta of 1.61.
Greenwich LifeSciences (NASDAQ:GLSI – Get Free Report) last issued its quarterly earnings results on Wednesday, August 14th. The company reported ($0.20) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.20). On average, equities analysts forecast that Greenwich LifeSciences will post -0.81 EPS for the current year.
Insider Buying and Selling
Hedge Funds Weigh In On Greenwich LifeSciences
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. raised its stake in shares of Greenwich LifeSciences by 0.6% in the first quarter. Vanguard Group Inc. now owns 223,102 shares of the company’s stock valued at $4,449,000 after acquiring an additional 1,420 shares in the last quarter. Rhumbline Advisers purchased a new stake in Greenwich LifeSciences during the 2nd quarter worth about $117,000. Finally, Bank of New York Mellon Corp acquired a new stake in Greenwich LifeSciences in the 2nd quarter valued at about $264,000. Hedge funds and other institutional investors own 4.16% of the company’s stock.
Analysts Set New Price Targets
Separately, HC Wainwright upped their price objective on shares of Greenwich LifeSciences from $36.00 to $38.00 and gave the company a “buy” rating in a report on Friday, August 23rd.
View Our Latest Report on GLSI
About Greenwich LifeSciences
Greenwich LifeSciences, Inc, a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery.
See Also
- Five stocks we like better than Greenwich LifeSciences
- Consumer Staples Stocks, Explained
- Why Lennar Stock Could Be the Best Play in the Housing Market
- Buy P&G Now, Before It Sets A New All-Time High
- 2 Energy Stocks Fueling the AI Datacenter Boom
- Low PE Growth Stocks: Unlocking Investment Opportunities
- Will Marinus Pharmaceuticals Be the Next Big Winner in Biotech?
Receive News & Ratings for Greenwich LifeSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Greenwich LifeSciences and related companies with MarketBeat.com's FREE daily email newsletter.